Dr. Sami Ibrahimi is an oncologist in Oklahoma City, Oklahoma and is affiliated with OU Health-University of Oklahoma Medical Center. He received his medical degree from University of Jordan Faculty of Medicine and has been in practice between 11-20 years. Dr. Sami Ibrahimi has expertise in treating chronic leukemia, lymphoma, among other conditions - see all areas of expertise. Dr. Sami Ibrahimi accepts Medicare, Aetna, Humana, Blue Cross, United Healthcare - see other insurance plans accepted. Dr. Sami Ibrahimi is highly recommended by patients.
Frequently asked questions regarding Dr. Sami Ibrahimi, M.D.
Dr. Sami Ibrahimi, M.D.'s email address is available to verified Dmand AI users. Their primary practice is located at Oklahoma Children's Hospital in Oklahoma City, Oklahoma. Sign up for a free trial to reveal their direct contact information.
Dr. Sami Ibrahimi, M.D.'s direct phone number is available to Dmand AI subscribers. To access their direct number, start a free trial.
Dr. Sami Ibrahimi, M.D. is a Hematology & Oncology Physician physician currently practicing at Oklahoma Children's Hospital in Oklahoma City, Oklahoma. They hold admitting privileges at 1 hospital(s), including O U MEDICAL CENTER. To see all the affiliations of Dr. Sami Ibrahimi, M.D., start a free trial.
Dr. Sami Ibrahimi, M.D. is a board-certified Hematology & Oncology Physician physician with a subspecialty in Hematology & Oncology. They practice at Oklahoma Children's Hospital in Oklahoma City, Oklahoma.
Dr. Sami Ibrahimi, M.D. performs procedures across 610 clinical categories. Their most commonly billed procedures based on Medicare claims data include , , and . Full procedure and CPT code data is available to Dmand AI subscribers, start a free trial.
Dr. Sami Ibrahimi, M.D.'s National Provider Identifier (NPI) is 1295081511. This is a public identifier issued by CMS and can be verified at the NPPES NPI Registry. Their primary taxonomy code is 207RH0003X, corresponding to Hematology & Oncology Physician.
The EHR and practice technology used by Dr. Sami Ibrahimi, M.D. at Oklahoma Children's Hospital is available to Dmand AI subscribers. Sign up for a free trial to unlock the full technology stack.
Dr. Sami Ibrahimi, M.D. accepts 6 insurance plans. A full list of accepted payers is available in the profile above.
Dr. Sami Ibrahimi, M.D. holds hospital privileges at 1 institution(s). Their primary affiliation is O U MEDICAL CENTER in Oklahoma City, Oklahoma.
Dr. Sami Ibrahimi, M.D. is board certified by American Board of Internal Medicine in Internal Medicine with subspecialty certification in Hematology. They have maintained this certification since .
Dr. Sami Ibrahimi, M.D. received their medical degree from University of Jordan Faculty of Medicine in 2010. They completed their Internal Medicine residency at UMass Chan - Baystate and a fellowship in Hematology and Medical Oncology at University of Oklahoma Health Sciences Center.
Based on CMS Medicare Part B claims data, Dr. Sami Ibrahimi, M.D. served approximately 304 Medicare beneficiaries in 2023. Total patient volume including non-Medicare patients is available to Dmand AI subscribers.
Dr. Sami Ibrahimi, M.D. is affiliated with OU HEALTH PARTNERS INC, a large (20+ physician) practice with 596 physicians based in Oklahoma City, Oklahoma. The practice is independently owned.
Dr. Sami Ibrahimi, M.D. has 31 indexed publications on record and has been listed as a principal investigator on 8 clinical trial(s). Their research activity is available to Dmand AI subscribers. Sign up for a free trial to unlock their full research activity.
Start today — no contract required
Identify. Engage. Convert.
Stop stitching together Definitive, ZoomInfo, and a separate outreach tool. Dmand gives Health IT GTM teams everything they need to find verified healthcare providers and executives, enrich contacts, and book more meetings — in one platform.
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Conditions:Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaDouble-Expressor LymphomaNeoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Conditions:Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaLymphoplasmacytic LymphomaGrade 3b Follicular LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell Type
Insurance Plans Accepted by Dr. Sami Ibrahimi, M.D.
Insurance Carrier
All Carriersarrow_drop_down
Plan Type
All Plansarrow_drop_down
Aetna
EPOHMOPOSPPOMedicare
Blue Cross Blue Shield of Michigan
HMOPOSPPO
CMS Medicare
Medicare
HCSC
PPO
Humana
PPOMedicare
United Healthcare
HMOPOSPPOMedicare
Dr. Sami Ibrahimi, M.D. Practice Locations
O U MEDICAL CENTERPrimary
Hospital • Oklahoma City, OK
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Intravascular Large B-Cell Lymphoma
Nodular Lymphocyte Predominant B-Cell Lymphoma
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma